Eris Lifescience gets CDSCO panel nod to study FDC of Metoprolol Succinate, Dapagliflozin

Published On 2023-01-21 11:00 GMT   |   Update On 2023-10-06 11:41 GMT
Advertisement

New Delhi: Directing to present bioequivalence (BE) study results in the Subject Expert Committee (SEC) before initiating the Phase III clinical trial, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to drug maker Eris for conducting bioequivalence (BE) study and Phase III clinical trial of the fixed-dose combination drug Metoprolol Succinate plus Dapagliflozin.

Advertisement

This came after the firm presented its proposal along with BE and Phase III CT protocol.

Metoprolol is in a class of medications called beta blockers. It works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure. Metoprolol is used alone or in combination with other medications to treat high blood pressure. It also is used to prevent angina (chest pain) and to improve survival after a heart attack. Metoprolol also is used in combination with other medications to treat heart failure.

Dapagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. By inhibiting SGLT2, dapagliflozin blocks reabsorption of filtered glucose in the kidney, increasing urinary glucose excretion and reducing blood glucose levels. Its mechanism of action is independent of pancreatic β cell function and modulation of insulin sensitivity.

At the recent SEC meeting for Cardiovascular & Renal held on the 11th of January 2023, the expert panel reviewed the proposal along with BE and Phase III CT protocol of the FDC drug Metoprolol Succinate plus Dapagliflozin

After detailed deliberation, the committee recommended the grant of permission to conduct the proposed BE and Phase III CT with the condition that BE study results should be presented in the SEC before initiating the Phase III CT.

Also Read:CDSCO Panel allows Cipla to waive requirements for phase 4 study of tocilizumab inj for giant cell arthritis

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News